{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:20Z","timestamp":1759334240547,"version":"build-2065373602"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170789"],"award-info":[{"award-number":["82170789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03625-6","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:13:52Z","timestamp":1759234432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuhang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tailai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"3625_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3625_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.trecan.2019.05.011","volume":"5","author":"R Ghandour","year":"2019","unstructured":"Ghandour R, Singla N, Lotan Y. Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer. Trends Cancer. 2019;5(7):426\u201339.","journal-title":"Trends Cancer"},{"key":"3625_CR3","doi-asserted-by":"crossref","unstructured":"Im SW et al. Genomic landscape of Young-Onset bladder cancer and its prognostic implications on adult bladder cancer. Cancers (Basel), 2020. 12(2).","DOI":"10.3390\/cancers12020307"},{"issue":"9","key":"3625_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(05)70315-6","volume":"6","author":"N Malats","year":"2005","unstructured":"Malats N, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678\u201386.","journal-title":"Lancet Oncol"},{"key":"3625_CR5","doi-asserted-by":"publisher","first-page":"110703","DOI":"10.1016\/j.biopha.2020.110703","volume":"131","author":"M Taheri","year":"2020","unstructured":"Taheri M, et al. Expression profile of MicroRNAs in bladder cancer and their application as biomarkers. Biomed Pharmacother. 2020;131:110703.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3625_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.eururo.2014.07.033","volume":"66","author":"A Masson-Lecomte","year":"2014","unstructured":"Masson-Lecomte A, et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol. 2014;66(6):1078\u201391.","journal-title":"Eur Urol"},{"issue":"1","key":"3625_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3625_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"3","key":"3625_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322.","journal-title":"Cancer Cell"},{"issue":"10","key":"3625_CR10","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.7150\/ijbs.35541","volume":"15","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, et al. EFEMP2 suppresses epithelial-mesenchymal transition via Wnt\/\u03b2-catenin signaling pathway in human bladder cancer. Int J Biol Sci. 2019;15(10):2139\u201355.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3625_CR11","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619.","journal-title":"Nat Commun"},{"issue":"3","key":"3625_CR12","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1002\/ctm2.694","volume":"12","author":"D Jovic","year":"2022","unstructured":"Jovic D, et al. Single-cell RNA sequencing technologies and applications: A brief overview. Clin Transl Med. 2022;12(3):e694.","journal-title":"Clin Transl Med"},{"issue":"6190","key":"3625_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396\u2013401.","journal-title":"Science"},{"issue":"1","key":"3625_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, et al. Inference and analysis of cell-cell communication using cellchat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"issue":"12","key":"3625_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"1","key":"3625_CR16","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen Z, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11(1):5077.","journal-title":"Nat Commun"},{"issue":"3","key":"3625_CR17","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3625_CR18","doi-asserted-by":"publisher","first-page":"800967","DOI":"10.3389\/fcell.2021.800967","volume":"9","author":"H Li","year":"2021","unstructured":"Li H, et al. TNF Family-Based signature predicts prognosis, tumor microenvironment, and molecular subtypes in bladder carcinoma. Front Cell Dev Biol. 2021;9:800967.","journal-title":"Front Cell Dev Biol"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3.","journal-title":"Mol Cancer"},{"issue":"1","key":"3625_CR20","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"NA Marzouka","year":"2018","unstructured":"Marzouka NA, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737.","journal-title":"Sci Rep"},{"issue":"8","key":"3625_CR21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3625_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","volume":"110","author":"Q Mo","year":"2018","unstructured":"Mo Q, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst. 2018;110(5):448\u201359.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3625_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, et al. A consensus molecular classification of Muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"issue":"10031","key":"3625_CR24","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"1","key":"3625_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, et al. European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"6","key":"3625_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with Intermediate- and High-risk Non-Muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046\u201352.","journal-title":"Eur Urol"},{"issue":"4","key":"3625_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","volume":"65","author":"JA Witjes","year":"2014","unstructured":"Witjes JA, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778\u201392.","journal-title":"Eur Urol"},{"issue":"1","key":"3625_CR28","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1038\/s41467-022-34495-z","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Single cell sequencing reveals that CD39 Inhibition mediates changes to the tumor microenvironment. Nat Commun. 2022;13(1):6740.","journal-title":"Nat Commun"},{"issue":"34","key":"3625_CR29","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with Muscle-Invasive urothelial bladder carcinoma (PURE-01): an Open-Label, Single-Arm, phase II study. J Clin Oncol. 2018;36(34):3353\u201360.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3625_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3625_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34(3):289\u201399.","journal-title":"Ann Oncol"},{"issue":"6","key":"3625_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","volume":"76","author":"SA Niglio","year":"2019","unstructured":"Niglio SA, et al. Programmed death-1 or programmed death Ligand-1 Blockade in patients with Platinum-resistant metastatic urothelial cancer: A systematic review and Meta-analysis. Eur Urol. 2019;76(6):782\u20139.","journal-title":"Eur Urol"},{"issue":"1","key":"3625_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee HW, et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12(1):47.","journal-title":"Genome Med"},{"issue":"3","key":"3625_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, et al. Single-Cell atlas of lineage states, tumor microenvironment, and Subtype-Specific expression programs in gastric cancer. Cancer Discov. 2022;12(3):670\u201391.","journal-title":"Cancer Discov"},{"issue":"1","key":"3625_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-022-02783-y","volume":"23","author":"Z Liu","year":"2022","unstructured":"Liu Z, Sun D, Wang C. Evaluation of cell-cell interaction methods by integrating single-cell RNA sequencing data with Spatial information. Genome Biol. 2022;23(1):218.","journal-title":"Genome Biol"},{"issue":"1","key":"3625_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"1","key":"3625_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1756-9966-31-68","volume":"31","author":"A Van den Broeck","year":"2012","unstructured":"Van den Broeck A, et al. Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res. 2012;31(1):68.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3625_CR38","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","volume":"19","author":"DT Miyamoto","year":"2018","unstructured":"Miyamoto DT, et al. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018;19(12):e683\u201395.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3625_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas M, Todenh\u00f6fer T, Black PC. Urine biomarkers in bladder cancer - current status and future perspectives. Nat Rev Urol. 2023;20(10):597\u2013614.","journal-title":"Nat Rev Urol"},{"key":"3625_CR40","doi-asserted-by":"crossref","unstructured":"Georgantzoglou N et al. Extracellular vesicles as biomarkers carriers in bladder cancer: diagnosis, surveillance, and treatment. Int J Mol Sci, 2021. 22(5).","DOI":"10.3390\/ijms22052744"},{"issue":"9","key":"3625_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nrc.2017.58","volume":"17","author":"T Baslan","year":"2017","unstructured":"Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017;17(9):557\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3625_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3727\/105221617X15088670121925","volume":"18","author":"S Brivio","year":"2018","unstructured":"Brivio S, et al. Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview. Gene Expr. 2018;18(1):31\u201350.","journal-title":"Gene Expr"},{"issue":"9","key":"3625_CR43","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1007\/s11033-021-06648-8","volume":"48","author":"A Mishra","year":"2021","unstructured":"Mishra A, et al. An updated review on the role of the CXCL8-CXCR1\/2 axis in the progression and metastasis of breast cancer. Mol Biol Rep. 2021;48(9):6551\u201361.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"3625_CR44","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/2767-9764.CRC-23-0036","volume":"3","author":"BJ Bulen","year":"2023","unstructured":"Bulen BJ, et al. Validation of immunotherapy response score as predictive of Pan-solid tumor Anti-PD-1\/PD-L1 benefit. Cancer Res Commun. 2023;3(7):1335\u201349.","journal-title":"Cancer Res Commun"},{"issue":"2","key":"3625_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of Circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272\u2013e2879.","journal-title":"Cancer Cell"},{"key":"3625_CR46","doi-asserted-by":"publisher","first-page":"1168635","DOI":"10.3389\/fimmu.2023.1168635","volume":"14","author":"A Domokos","year":"2023","unstructured":"Domokos A, et al. The transcriptional control of the VEGFA-VEGFR1 (FLT1) axis in alternatively polarized murine and human macrophages. Front Immunol. 2023;14:1168635.","journal-title":"Front Immunol"},{"issue":"12","key":"3625_CR47","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, et al. FLT1 and its ligands VEGFB and plgf: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3625_CR48","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41467-017-00728-9","volume":"8","author":"S Dushyanthen","year":"2017","unstructured":"Dushyanthen S, et al. Agonist immunotherapy restores T cell function following MEK Inhibition improving efficacy in breast cancer. Nat Commun. 2017;8(1):606.","journal-title":"Nat Commun"},{"issue":"10","key":"3625_CR49","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/jca.49707","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12(10):3011\u201323.","journal-title":"J Cancer"},{"issue":"2","key":"3625_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10014-010-0013-1","volume":"28","author":"M Terasaki","year":"2011","unstructured":"Terasaki M, et al. CXCL12\/CXCR4 signaling in malignant brain tumors: a potential Pharmacological therapeutic target. Brain Tumor Pathol. 2011;28(2):89\u201397.","journal-title":"Brain Tumor Pathol"},{"key":"3625_CR51","doi-asserted-by":"publisher","first-page":"114491","DOI":"10.1016\/j.biopha.2023.114491","volume":"161","author":"P Pandey","year":"2023","unstructured":"Pandey P, et al. New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomed Pharmacother. 2023;161:114491.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"3625_CR52","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41388-021-01685-w","volume":"40","author":"H Yoon","year":"2021","unstructured":"Yoon H, et al. Cancer-associated fibroblast secretion of PDGFC promotes Gastrointestinal stromal tumor growth and metastasis. Oncogene. 2021;40(11):1957\u201373.","journal-title":"Oncogene"},{"issue":"1","key":"3625_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"3625_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/gutjnl-2020-322924","volume":"71","author":"TX Huang","year":"2022","unstructured":"Huang TX, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2022;71(2):333\u201344.","journal-title":"Gut"},{"issue":"3","key":"3625_CR55","doi-asserted-by":"publisher","first-page":"114","DOI":"10.55133\/eji.280312","volume":"28","author":"WT El-Sherif","year":"2021","unstructured":"El-Sherif WT, et al. CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients. Egypt J Immunol. 2021;28(3):114\u201326.","journal-title":"Egypt J Immunol"},{"issue":"13","key":"3625_CR56","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-12-3015","volume":"19","author":"K Beider","year":"2013","unstructured":"Beider K, et al. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 2013;19(13):3495\u2013507.","journal-title":"Clin Cancer Res"},{"key":"3625_CR57","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","volume":"10","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;10:1672.","journal-title":"Front Oncol"},{"issue":"1","key":"3625_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12885-021-07930-5","volume":"21","author":"F Chen","year":"2021","unstructured":"Chen F, Wang Q, Zhou Y. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer. BMC Cancer. 2021;21(1):244.","journal-title":"BMC Cancer"},{"issue":"1","key":"3625_CR59","doi-asserted-by":"publisher","first-page":"pbac002","DOI":"10.1093\/pcmedi\/pbac002","volume":"5","author":"L Wen","year":"2022","unstructured":"Wen L, Tang F. Recent advances in single-cell sequencing technologies. Precis Clin Med. 2022;5(1):pbac002.","journal-title":"Precis Clin Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03625-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:20Z","timestamp":1759237580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03625-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was ethically approved by the Ethics Review Committee of Xiangya Hospital, Central South University (Changsha, PR, China), and was conducted in accordance with the Declaration of Helsinki ( for-medical-research-involving-human-subjects\/). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1784"}}